Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Prevention of microalbuminuria in patients with type 2 diabetes and hypertension.

Menne J, Izzo JL Jr, Ito S, Januszewicz A, Katayama S, Chatzykirkou C, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, Haller H; ROADMAP investigators.

J Hypertens. 2012 Apr;30(4):811-8; discussion 818. doi: 10.1097/HJH.0b013e328351856d. Erratum in: J Hypertens. 2012 Aug;30(8):1679.

PMID:
22418908
2.

Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes.

Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators.

N Engl J Med. 2011 Mar 10;364(10):907-17. doi: 10.1056/NEJMoa1007994.

3.

Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.

Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL Jr, Januszewicz A.

J Hypertens. 2006 Feb;24(2):403-8.

PMID:
16508590
4.
5.

Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.

Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G; BENEDICT Study Group.

J Am Soc Nephrol. 2006 Dec;17(12):3472-81. Epub 2006 Nov 2.

7.
8.

Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus.

Fogari R, Derosa G, Zoppi A, Rinaldi A, Preti P, Lazzari P, Mugellini A.

Hypertens Res. 2008 Jan;31(1):43-50. doi: 10.1291/hypres.31.43.

PMID:
18360017
9.

Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies.

Omboni S, Malacco E, Mallion JM, Volpe M, Zanchetti A; Study Group.

J Hypertens. 2012 Jul;30(7):1468-77. doi: 10.1097/HJH.0b013e32835466ac.

PMID:
22573127
10.

Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study.

Kawai T, Takei I, Shimada A, Hirata T, Tanaka K, Saisho Y, Irie J, Horimai C, Matsumoto H, Itoh H.

Clin Drug Investig. 2011;31(4):237-45. doi: 10.2165/11586510-000000000-00000.

PMID:
21184621
11.

Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study.

Marre M, Puig JG, Kokot F, Fernandez M, Jermendy G, Opie L, Moyseev V, Scheen A, Ionescu-Tirgoviste C, Saldanha MH, Halabe A, Williams B, Mion Júnior D, Ruiz M, Hermansen K, Tuomilehto J, Finizola B, Gallois Y, Amouyel P, Ollivier JP, Asmar R.

J Hypertens. 2004 Aug;22(8):1613-22.

12.

Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients.

Fogari R, Malamani G, Corradi L, Mugellini A, Preti P, Zoppi A, Derosa G.

Adv Ther. 2010 Jan;27(1):48-55. doi: 10.1007/s12325-010-0002-0. Epub 2010 Feb 19.

PMID:
20174905
13.

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.

Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators.

Circulation. 2002 Aug 6;106(6):672-8.

14.

Efficacy of single-pill perindopril/indapamide in patients with hypertension and type 2 diabetes.

Netchessova TA, Shepelkevich AP, Gorbat TV; NIKA Study Group.

High Blood Press Cardiovasc Prev. 2014 Mar;21(1):63-9. doi: 10.1007/s40292-013-0036-x. Epub 2013 Dec 20.

PMID:
24357222
15.

Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria.

Weir MR, Hollenberg NK, Zappe DH, Meng X, Parving HH, Viberti G, Remuzzi G.

J Hypertens. 2010 Jan;28(1):186-93. doi: 10.1097/HJH.0b013e328332bd61.

PMID:
19809363
17.

Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).

Januszewicz A, Ritz E, Viberti G, Mimran A, Rabelink AJ, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL Jr, Haller H.

J Hum Hypertens. 2011 Nov;25(11):679-85. doi: 10.1038/jhh.2010.111. Epub 2010 Dec 9.

PMID:
21150933
18.

Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients.

Weir MR, Hollenberg NK, Remuzzi G, Zappe DH, Meng X, Parving HH.

J Hypertens. 2011 Oct;29(10):2031-7. doi: 10.1097/HJH.0b013e32834a8a25.

PMID:
21841500
20.

Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension.

Kato J, Yokota N, Tamaki N, Kariya S, Kita T, Ayabe T, Eto T, Kitamura K.

Hypertens Res. 2011 Mar;34(3):331-5. doi: 10.1038/hr.2010.233. Epub 2010 Dec 2.

PMID:
21124326

Supplemental Content

Support Center